ID   CCRF/VCR1000
AC   CVCL_D546
SY   CCRF VCR1000; CCRF-VCR 1000; CCRF VCR 1000; CCRF-CEM/VCR-1000; CEM-VCR 1000; CEM/VCR1000; VCR1000
DR   cancercelllines; CVCL_D546
DR   ChEMBL-Cells; CHEMBL3307393
DR   ChEMBL-Targets; CHEMBL614540
DR   PubChem_Cell_line; CVCL_D546
DR   Wikidata; Q54809052
RX   PubMed=1698543;
RX   PubMed=12482398;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
CC   Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0207 ! CCRF-CEM
SX   Female
AG   3Y11M
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=1698543;
RA   Kimmig A., Gekeler V., Neumann M., Frese G., Handgretinger R.,
RA   Kardos G., Diddens H., Niethammer D.;
RT   "Susceptibility of multidrug-resistant human leukemia cell lines to
RT   human interleukin 2-activated killer cells.";
RL   Cancer Res. 50:6793-6799(1990).
//
RX   PubMed=12482398; DOI=10.1006/bcmd.2002.0530;
RA   Efferth T., Verdorfer I., Miyachi H., Sauerbrey A., Drexler H.G.,
RA   Chitambar C.R., Haber M., Gebhart E.;
RT   "Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM
RT   leukemia cell lines.";
RL   Blood Cells Mol. Dis. 29:1-13(2002).
//